You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the DELSTRIGO (doravirine; lamivudine; tenofovir disoproxil fumarate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR DELSTRIGO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DELSTRIGO

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02629822 ↗	Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2016-01-14	The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a single fixed-dose combination (FDC) tablet of DOR/3TC/TDF 100 mg/300 mg/300 mg in treatment-naïve HIV-1 infected participants with select non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance-associated mutations.
NCT04233372 ↗	Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study	Recruiting	Dr. Josep Mallolas	Phase 4	2020-08-27	Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
NCT04233372 ↗	Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study	Recruiting	David Garcia Cinca	Phase 4	2020-08-27	Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DELSTRIGO

Condition Name

Chart
Table

Condition Name for DELSTRIGO
Intervention	Trials
HIV	5
HIV-1-infection	3
Weight Gain	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DELSTRIGO
Intervention	Trials
HIV Infections	4
Acquired Immunodeficiency Syndrome	4
Body Weight	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DELSTRIGO

Trials by Country

Map
Table

Trials by Country for DELSTRIGO
Location	Trials
United States	8
South Africa	4
Spain	3
United Kingdom	2
France	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DELSTRIGO
Location	Trials
Texas	1
Pennsylvania	1
New Jersey	1
Maryland	1
Illinois	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DELSTRIGO

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DELSTRIGO
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DELSTRIGO
Clinical Trial Phase	Trials
Recruiting	5
Not yet recruiting	4
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DELSTRIGO

Sponsor Name

Chart
Table

Sponsor Name for DELSTRIGO
Sponsor	Trials
Professor Francois Venter	3
Merck Sharp & Dohme LLC	2
Merck Sharp & Dohme Corp.	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DELSTRIGO
Sponsor	Trials
Other	16
Industry	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.